Neisseria meningitidis serogroup b nhba fusion protein antigen
- Generic Name
- Neisseria meningitidis serogroup b nhba fusion protein antigen
- Brand Names
- Bexsero
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 28E911Y7AE
- Associated Conditions
- Serogroup B Meningococcal Meningitis
BIYELA - Bexsero Immunisation in Young Women in Africa
Phase 3
Recruiting
- Conditions
- Gonorrhea of AnusGonorrheaGonorrhea of PharynxGonorrhea of Cervix
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1100
- Registration Number
- NCT06446752
- Locations
- ๐ฟ๐ฆ
Desmond Tutu Health Foundation - Emavundleni Research Centre, Cape Town, South Africa
๐ฟ๐ฆDesmond Tutu Health Foundation - Masiphumulele Site, Cape Town, South Africa
๐ฟ๐ฆKhayelitsha Vuka Research Clinic, Cape Town, South Africa
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT06033261
- Locations
- ๐บ๐ธ
Accel Clinical Sites Network - Cahaba Medical Care, Birmingham, Alabama, United States
๐บ๐ธAcclaim Clinical Research, San Diego, California, United States
๐บ๐ธNoble Clinical Research, Tucson, Arizona, United States
Meningococcal B Vaccine in Patients with Asplenia
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 80
- Registration Number
- NCT06025487
- Locations
- ๐ฆ๐น
Medical University Vienna, Vienna, Austria
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Phase 3
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1196
- Registration Number
- NCT03621670
- Locations
- ๐ฌ๐ง
GSK Investigational Site, Edinburg, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath